NCT03052478View on ClinicalTrials.gov

Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 10, 2017

Primary Completion Date

December 31, 2019

Study Completion Date

September 10, 2020

Conditions
Stomach Neoplasms
Interventions
DRUG

Vismodegib 150 mg

Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.

Trial Locations (1)

135710

Samsung Medical Center, Seoul

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT03052478 - Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression | Biotech Hunter | Biotech Hunter